𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Platelet dysfunction in a patient with the Opitz (BBBG) syndrome

✍ Scribed by Kapoor, Rohit ;Rodgers, George M.


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
316 KB
Volume
43
Category
Article
ISSN
0148-7299

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Ring chromosome 22 karyotype in a patien
✍ Christodoulou, John ;Bankier, Agnes ;Loughnan, Peter πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 257 KB πŸ‘ 1 views

## To the Editor: The Opitz or BBBG syndrome is an autosomal dominant disorder characterized by facial anomalies and multiple congenital abnormalities. Recent evidence would suggest that the Opitz and BBB syndromes form a spectrum of the same condition Verloes et al., 19891 and it has been sugges

Graves disease in a patient with the del
✍ Jones, Kenneth Lee ;Carey, Dennis E. ;Opitz, John M. πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 233 KB πŸ‘ 2 views

## Abstract We report the first known patient with a del(18p) and Graves disease. This deletion has previously been reported to be associated with autoimmune thyroid disease and, perhaps, with inborn errors of thyroxin biosynthesis. We present the clinical and histological information on this patie

Normal cognition and behavior in a Smith
✍ Mueller, C. ;Patel, S. ;Irons, M. ;Antshel, K. ;Salen, G. ;Tint, G.S. ;Bay, C. πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 487 KB

## Abstract Smith‐Lemli‐Opitz syndrome (SLOS) is an autosomal recessive disorder of cholesterol biosynthesis. It is caused by mutations in the gene encoding the enzyme 7‐dehydrocholesterol Ξ”7‐reductase (DHCR7), which catalyzes the final step in cholesterol biosynthesis, usually resulting in cholest

Clinical effects of cholesterol suppleme
✍ Elias, Ellen R.; Irons, Mira B.; Hurley, Anne D.; Tint, G. Stephen; Salen, Geral πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 153 KB πŸ‘ 2 views

We describe the clinical effects of cholesterol supplementation in 6 children with the RSH-"Smith-Lemli-Opitz" syndrome (SLOS). The children ranged in age from birth to 11 years at the onset of therapy, with pretreatment cholesterol levels ranging from 8 to 62 mg/dl. Clinical benefits of therapy wer